Objective: To investigate the influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction. Methods: A total of 1...Objective: To investigate the influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction. Methods: A total of 177 cases of patients with convalescent cerebral infarction were retrospectively reviewed and then divided into the control group (n=109) and the Xiaoshuan enteric-coated capsules group (n=68). Control group received aniracetam therapy on the basis of routine treatment, and Xiaoshuan enteric-coated capsules group received Xiaoshuan enteric-coated capsules + aniracetam therapy on the basis of routine treatment. The differences in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents were compared between the two groups. Results: Before treatment, there was no statistically significant difference in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents between the two groups. After treatment, ultrasound cerebral blood perfusion parameters PSV and TMV levels in Xiaoshuan enteric-coated capsules group were higher than those in control group whereas RI level was lower than that in control group;serum neurotrophy indexes bFGF, BDNF and VEGF contents were higher than those of control group;serum nerve injury indexes GFAP, NSE, UCH-L1 and S100B contents were lower than those of control group. Conclusion: Xiaoshuan enteric-coated capsules + aniracetam therapy can significantly increase cerebral blood perfusion and optimize nerve function in patients with convalescent cerebral infarction.展开更多
Objective:To explore the clinical efficacy of Xiaoshuan enteric-coated capsule(XSECC)in treating ce-rebral infarction and its potential mechanism of action.Methods:Patients with acute ischemic stroke(AIS)of the qi def...Objective:To explore the clinical efficacy of Xiaoshuan enteric-coated capsule(XSECC)in treating ce-rebral infarction and its potential mechanism of action.Methods:Patients with acute ischemic stroke(AIS)of the qi deficiency and blood stasis type were randomly assigned to the control and observation groups.They were evaluated using the National In-stitutes of Health Stroke Scale(NIHSS),Activities of Daily Living(ADL),Hachinskilnchemic Scale(HIS),Barthel Index(BI),clinical efficacy scores,and TCM syndrome scores on days 0,14,30,and 90.Furthermore,VEGF and BDNF levels were measured on days 30 and 90.Finally,we analyzed the changes in each scale score and vascular neurological factor in both groups.Results:After 14 days of treatment,the difference values in NIHSS,ADL,and BI were higher,and TCM syndrome and clinical efficacy scores were increased in the observation group compared with those of the control group(all P<0.05).After 30 days,the NIHSS,ADL,HIS,and TCM syndrome scores were decreased compared with those of the control group,while BI and clinical efficacy scores were increased(all P<0.05).After 90 days,the difference value in ADL was higher,and TCM syndrome score was increased in the observation group compared with that of the control group(P=0.047,P=0.005,respectively).The levels of VEGF and BDNF were higher in the observation group than in the control group on days 14,30,and 90(all P<0.05).VEGF and BDNF levels on day 0 were associated with prognosis of patients with AIS;therefore,they have a predictive value for the prognosis of acute cerebral infarction.Conclusions:XSECC therapy can improve clinical outcomes in patients with acute and recurrent cerebral infarctions.Its mechanism of action may be associated with the secretion of VEGF and BDNF.展开更多
Objective To investigate the effects of Weikang Capsule(胃康胶囊,WKC)on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy(MCCE).Methods Patients taking enteric-co...Objective To investigate the effects of Weikang Capsule(胃康胶囊,WKC)on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy(MCCE).Methods Patients taking enteric-coated aspirin aged 40-75 years were enrolled in Beijing Anzhen Hospital,Capital Medical University from January 2019 to December 2019.The patients continued taking aspirin Tablet(100 mg per day)and underwent MCCE before and after 1-month combined treatment with WKC(0.9 g per time orally,3 times per day).The gastrointestinal symptom score,gastric Lanza score,the duodenal,jejunal and ileal mucosal injury scores were used to evaluate the gastrointestinal injury before and after treatment.Adverse events including nausea,vomiting,abdominal pain,abdominal distension,abdominal discomfort,dizziness,or headache during MCCE and combined treatment were observed and recorded.Results Twenty-two patients(male/female,13/9)taking enteric-coated aspirin aged 59.5±11.3 years with a duration of aspirin use of 28.0(1.0,48.0)months were recruited.Compared with pre-treatment,the gastrointestinal symptom rating scale scores,gastric Lanza scores,and duodenal mucosal injury scores were significantly reduced after 1-month WKC treatment(P<0.05),and jejunal and ileal mucosal injury scores showed no obvious change.No adverse events occurred during the trial.Conclusions WKC can alleviate gastrointestinal symptoms,as well as gastric and duodenal mucosal injuries,in patients taking enteric-coated aspirin;it does not aggravate jejunal or ileal mucosal injury,which may be an effective alternative for these patients(Clinical trial registry No.ChiCTR1900025451).展开更多
Background Elevated fibrinogen （Fg） level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess...Background Elevated fibrinogen （Fg） level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess the effects of one-year therapy with oral lumbrokinase enteric-coated capsules on secondary ischemic stroke prevention.展开更多
文摘Objective: To investigate the influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction. Methods: A total of 177 cases of patients with convalescent cerebral infarction were retrospectively reviewed and then divided into the control group (n=109) and the Xiaoshuan enteric-coated capsules group (n=68). Control group received aniracetam therapy on the basis of routine treatment, and Xiaoshuan enteric-coated capsules group received Xiaoshuan enteric-coated capsules + aniracetam therapy on the basis of routine treatment. The differences in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents were compared between the two groups. Results: Before treatment, there was no statistically significant difference in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents between the two groups. After treatment, ultrasound cerebral blood perfusion parameters PSV and TMV levels in Xiaoshuan enteric-coated capsules group were higher than those in control group whereas RI level was lower than that in control group;serum neurotrophy indexes bFGF, BDNF and VEGF contents were higher than those of control group;serum nerve injury indexes GFAP, NSE, UCH-L1 and S100B contents were lower than those of control group. Conclusion: Xiaoshuan enteric-coated capsules + aniracetam therapy can significantly increase cerebral blood perfusion and optimize nerve function in patients with convalescent cerebral infarction.
基金funded by the project of the National Natural Science Foundation of China(82004028)the Shanxi Provincial Basic Research Program for Young Scientists(202203021212079)+2 种基金Grant of Innovative Young Talent Team of Shanxi Science and Technology Department(202204051001028)Young Scientists Cultivation Project of Shanxi University of Chinese Medicine(2021PY-QN-09)Key Specialty Cultivation Program of National Administration of Traditional Chinese Medicine during the“Twelfth Five-Year Plan”of China:Department of Geriatrics,Shanxi Provincial People's Hospital([2012]2-2-209).
文摘Objective:To explore the clinical efficacy of Xiaoshuan enteric-coated capsule(XSECC)in treating ce-rebral infarction and its potential mechanism of action.Methods:Patients with acute ischemic stroke(AIS)of the qi deficiency and blood stasis type were randomly assigned to the control and observation groups.They were evaluated using the National In-stitutes of Health Stroke Scale(NIHSS),Activities of Daily Living(ADL),Hachinskilnchemic Scale(HIS),Barthel Index(BI),clinical efficacy scores,and TCM syndrome scores on days 0,14,30,and 90.Furthermore,VEGF and BDNF levels were measured on days 30 and 90.Finally,we analyzed the changes in each scale score and vascular neurological factor in both groups.Results:After 14 days of treatment,the difference values in NIHSS,ADL,and BI were higher,and TCM syndrome and clinical efficacy scores were increased in the observation group compared with those of the control group(all P<0.05).After 30 days,the NIHSS,ADL,HIS,and TCM syndrome scores were decreased compared with those of the control group,while BI and clinical efficacy scores were increased(all P<0.05).After 90 days,the difference value in ADL was higher,and TCM syndrome score was increased in the observation group compared with that of the control group(P=0.047,P=0.005,respectively).The levels of VEGF and BDNF were higher in the observation group than in the control group on days 14,30,and 90(all P<0.05).VEGF and BDNF levels on day 0 were associated with prognosis of patients with AIS;therefore,they have a predictive value for the prognosis of acute cerebral infarction.Conclusions:XSECC therapy can improve clinical outcomes in patients with acute and recurrent cerebral infarctions.Its mechanism of action may be associated with the secretion of VEGF and BDNF.
基金Supported by Beijing Chinese Medicine Science and Technology Development Fund(No.JJ2018-02)。
文摘Objective To investigate the effects of Weikang Capsule(胃康胶囊,WKC)on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy(MCCE).Methods Patients taking enteric-coated aspirin aged 40-75 years were enrolled in Beijing Anzhen Hospital,Capital Medical University from January 2019 to December 2019.The patients continued taking aspirin Tablet(100 mg per day)and underwent MCCE before and after 1-month combined treatment with WKC(0.9 g per time orally,3 times per day).The gastrointestinal symptom score,gastric Lanza score,the duodenal,jejunal and ileal mucosal injury scores were used to evaluate the gastrointestinal injury before and after treatment.Adverse events including nausea,vomiting,abdominal pain,abdominal distension,abdominal discomfort,dizziness,or headache during MCCE and combined treatment were observed and recorded.Results Twenty-two patients(male/female,13/9)taking enteric-coated aspirin aged 59.5±11.3 years with a duration of aspirin use of 28.0(1.0,48.0)months were recruited.Compared with pre-treatment,the gastrointestinal symptom rating scale scores,gastric Lanza scores,and duodenal mucosal injury scores were significantly reduced after 1-month WKC treatment(P<0.05),and jejunal and ileal mucosal injury scores showed no obvious change.No adverse events occurred during the trial.Conclusions WKC can alleviate gastrointestinal symptoms,as well as gastric and duodenal mucosal injuries,in patients taking enteric-coated aspirin;it does not aggravate jejunal or ileal mucosal injury,which may be an effective alternative for these patients(Clinical trial registry No.ChiCTR1900025451).
文摘Background Elevated fibrinogen （Fg） level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess the effects of one-year therapy with oral lumbrokinase enteric-coated capsules on secondary ischemic stroke prevention.
